tiprankstipranks
Trending News
More News >
Jacobio Pharmaceuticals Group Co., Ltd. (HK:1167)
:1167
Hong Kong Market
Advertisement

Jacobio Pharmaceuticals Group Co., Ltd. (1167) Stock Statistics & Valuation Metrics

Compare
5 Followers

Total Valuation

Jacobio Pharmaceuticals Group Co., Ltd. has a market cap or net worth of HK$6.94B. The enterprise value is HK$2.51B.
Market CapHK$6.94B
Enterprise ValueHK$2.51B

Share Statistics

Jacobio Pharmaceuticals Group Co., Ltd. has 791,755,070 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding791,755,070
Owned by Insiders
Owned by Institutions

Financial Efficiency

Jacobio Pharmaceuticals Group Co., Ltd.’s return on equity (ROE) is -0.17 and return on invested capital (ROIC) is -15.92%.
Return on Equity (ROE)-0.17
Return on Assets (ROA)-0.11
Return on Invested Capital (ROIC)-15.92%
Return on Capital Employed (ROCE)-0.17
Revenue Per Employee605.87K
Profits Per Employee-605.87K
Employee Count257
Asset Turnover0.11
Inventory Turnover0.00

Valuation Ratios

The current PE Ratio of Jacobio Pharmaceuticals Group Co., Ltd. is ―. Jacobio Pharmaceuticals Group Co., Ltd.’s PEG ratio is 0.11.
PE Ratio
PS Ratio5.94
PB Ratio1.00
Price to Fair Value1.00
Price to FCF-10.72
Price to Operating Cash Flow-38.78
PEG Ratio0.11

Income Statement

In the last 12 months, Jacobio Pharmaceuticals Group Co., Ltd. had revenue of 155.71M and earned -155.71M in profits. Earnings per share was -0.20.
Revenue155.71M
Gross Profit155.71M
Operating Income-188.17M
Pretax Income-155.71M
Net Income-155.71M
EBITDA-192.36M
Earnings Per Share (EPS)-0.20

Cash Flow

In the last 12 months, operating cash flow was 106.31M and capital expenditures -6.61M, giving a free cash flow of 99.69M billion.
Operating Cash Flow106.31M
Free Cash Flow99.69M
Free Cash Flow per Share0.13

Dividends & Yields

Jacobio Pharmaceuticals Group Co., Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta1.33
52-Week Price Change345.60%
50-Day Moving Average9.16
200-Day Moving Average4.90
Relative Strength Index (RSI)37.68
Average Volume (3m)9.57M

Important Dates

Jacobio Pharmaceuticals Group Co., Ltd. upcoming earnings date is Mar 25, 2026, Before Open (Confirmed).
Last Earnings DateAug 29, 2025
Next Earnings DateMar 25, 2026
Ex-Dividend Date

Financial Position

Jacobio Pharmaceuticals Group Co., Ltd. as a current ratio of 4.89, with Debt / Equity ratio of 16.47%
Current Ratio4.89
Quick Ratio4.88
Debt to Market Cap0.08
Net Debt to EBITDA5.32
Interest Coverage Ratio-22.40

Taxes

In the past 12 months, Jacobio Pharmaceuticals Group Co., Ltd. has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00

Enterprise Valuation

Jacobio Pharmaceuticals Group Co., Ltd. EV to EBITDA ratio is 0.51, with an EV/FCF ratio of 1.14.
EV to Sales-0.63
EV to EBITDA0.51
EV to Free Cash Flow1.14
EV to Operating Cash Flow1.33

Balance Sheet

Jacobio Pharmaceuticals Group Co., Ltd. has HK$1.07B in cash and marketable securities with HK$143.01M in debt, giving a net cash position of HK$931.09M billion.
Cash & Marketable SecuritiesHK$1.07B
Total DebtHK$143.01M
Net CashHK$931.09M
Net Cash Per ShareHK$1.18
Tangible Book Value Per ShareHK$1.19

Margins

Gross margin is 100.00%, with operating margin of -120.85%, and net profit margin of -100.00%.
Gross Margin100.00%
Operating Margin-120.85%
Pretax Margin-100.00%
Net Profit Margin-100.00%
EBITDA Margin-123.54%
EBIT Margin-130.49%

Analyst Forecast

The average price target for Jacobio Pharmaceuticals Group Co., Ltd. is HK$5.30, which is 11.43% higher than the current price. The consensus rating is Hold
Price TargetHK$5.30
Price Target Upside-34.65% Downside
Analyst ConsensusHold
Analyst Count0
Revenue Growth Forecast770.20%
EPS Growth Forecast87.27%

Scores

Smart Score7
AI Score
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis